Top

Published in:

Open Access 01-12-2013 | Research

The role of interleukin 17 in Crohn’s disease-associated intestinal fibrosis

Authors: Paolo Biancheri, Sylvia LF Pender, Francesca Ammoscato, Paolo Giuffrida, Gianluca Sampietro, Sandro Ardizzone, Amir Ghanbari, Renata Curciarello, Alessandra Pasini, Giovanni Monteleone, Gino R Corazza, Thomas T MacDonald, Antonio Di Sabatino

Published in: Fibrogenesis & Tissue Repair | Issue 1/2013

Abstract

Background

Interleukin (IL)-17A and IL-17E (also known as IL-25) have been implicated in fibrosis in various tissues. However, the role of these cytokines in the development of intestinal strictures in Crohn’s disease (CD) has not been explored. We investigated the levels of IL-17A and IL-17E and their receptors in CD strictured and non-strictured gut, and the effects of IL-17A and IL-17E on CD myofibroblasts.

Results

IL-17A was significantly overexpressed in strictured compared with non-strictured CD tissues, whereas no significant difference was found in the expression of IL-17E or IL-17A and IL-17E receptors (IL-17RC and IL-17RB, respectively) in strictured and non-strictured CD areas. Strictured CD explants released significantly higher amounts of IL-17A than non-strictured explants, whereas no difference was found as for IL-17E, IL-6, or tumor necrosis factor-α production. IL-17A, but not IL-17E, significantly inhibited myofibroblast migration, and also significantly upregulated matrix metalloproteinase (MMP)-3, MMP-12, tissue inhibitor of metalloproteinase-1 and collagen production by myofibroblasts from strictured CD tissues.

Conclusions

Our results suggest that IL-17A, but not IL-17E, is pro-fibrotic in CD. Further studies are needed to clarify whether the therapeutic blockade of IL-17A through the anti-IL-17A monoclonal antibody secukinumab is able to counteract the fibrogenic process in CD.

Available only for authorised users

Wynn TA, Ramalingam TR: Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012, 18: 1028-1040. 10.1038/nm.2807.PubMedCentralCrossRefPubMed

Gabbiani G: The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003, 200: 500-503. 10.1002/path.1427.CrossRefPubMed

Wynn TA: Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004, 4: 583-594. 10.1038/nri1412.PubMedCentralCrossRefPubMed

Gaffen SL: Recent advances in the IL-17 cytokine family. Curr Opin Immunol. 2011, 23: 613-619. 10.1016/j.coi.2011.07.006.PubMedCentralCrossRefPubMed

Valente AJ, Yoshida T, Gardner JD, Somanna N, Delafontaine P, Chandrasekar B: Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1. Cell Signal. 2012, 24: 560-568. 10.1016/j.cellsig.2011.10.010.PubMedCentralCrossRefPubMed

Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, Iwaisako K, Liu X, Zhang M, Osterreicher CH, Stickel F, Ley K, Brenner DA, Kisseleva T: Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012, 143: 765-776. 10.1053/j.gastro.2012.05.049.PubMedCentralCrossRefPubMed

Okamoto Y, Hasegawa M, Matsushita T, Hamaguchi Y, Huu DL, Iwakura Y, Fujimoto M, Takehara K: Potential roles of interleukin-17A in the development of skin fibrosis in mice. Arthritis Rheum. 2012, 64: 3726-3735. 10.1002/art.34643.CrossRefPubMed

Mi S, Li Z, Yang HZ, Liu H, Wang JP, Ma YG, Wang XX, Liu HZ, Sun W, Hu ZW: Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol. 2011, 187: 3003-3014. 10.4049/jimmunol.1004081.CrossRefPubMed

Létuvé S, Lajoie-Kadoch S, Audusseau S, Rothenberg ME, Fiset PO, Ludwig MS, Hamid Q: IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. J Allergy Clin Immunol. 2006, 117: 590-596. 10.1016/j.jaci.2005.10.025.CrossRefPubMed

10.

Gregory LG, Jones CP, Walker SA, Sawant D, Gowers KH, Campbell GA, McKenzie AN, Lloyd CM: IL-25 drives remodelling in allergic airways disease induced by house dust mite. Thorax. 2013, 68: 82-90. 10.1136/thoraxjnl-2012-202003.PubMedCentralCrossRefPubMed

11.

Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles CH, Rampton DS, Corazza GR, Monteleone G, Di Sabatino A, Macdonald TT: Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009, 58: 1629-1636. 10.1136/gut.2009.182170.CrossRefPubMed

12.

Caruso R, Sarra M, Stolfi C, Rizzo A, Fina D, Fantini MC, Pallone F, MacDonald TT, Monteleone G: Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology. 2009, 136: 2270-2279. 10.1053/j.gastro.2009.02.049.CrossRefPubMed

13.

Burke JP, Mulsow JJ, O’Keane C, Docherty NG, Watson RW, O’Connell PR: Fibrogenesis in Crohn’s disease. Am J Gastroenterol. 2007, 102: 439-448. 10.1111/j.1572-0241.2006.01010.x.CrossRefPubMed

14.

Regan MC, Flavin BM, Fitzpatrick JM, O’Connell PR: Stricture formation in Crohn’s disease: the role of intestinal fibroblasts. Ann Surg. 2000, 231: 46-50. 10.1097/00000658-200001000-00007.PubMedCentralCrossRefPubMed

15.

Andoh A, Bamba S, Brittan M, Fujiyama Y, Wright NA: Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. Pharmacol Ther. 2007, 114: 94-106. 10.1016/j.pharmthera.2006.12.004.CrossRefPubMed

16.

Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NA, Picariello L, Cazzola P, Monteleone G, Tonelli F, Corazza GR, MacDonald TT, Pender SL: Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures. Gut. 2009, 58: 777-789. 10.1136/gut.2008.149096.CrossRefPubMed

17.

Okuno T, Andoh A, Bamba S, Araki Y, Fujiyama Y, Fujiyama M, Bamba T: Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts. Scand J Gastroenterol. 2002, 37: 317-324. 10.1080/003655202317284228.CrossRefPubMed

18.

Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005, 6: 1123-1132. 10.1038/ni1254.CrossRefPubMed

19.

Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Filì L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S: Phenotypic and functional features of human Th17. J Exp Med. 2007, 204: 1849-1861. 10.1084/jem.20070663.PubMedCentralCrossRefPubMed

20.

Steinman L: A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med. 2007, 13: 139-145. 10.1038/nm1551.CrossRefPubMed

21.

Monteleone I, Sarra M, Del Vecchio BG, Paoluzi OA, Franzè E, Fina D, Fabrizi A, MacDonald TT, Pallone F, Monteleone G: Characterization of IL-17A-producing cells in celiac disease mucosa. J Immunol. 2010, 184: 2211-2218. 10.4049/jimmunol.0901919.CrossRefPubMed

22.

Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A, Koganei K, Isobe K, Hibi T: IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease. Gut. 2008, 57: 1682-1689. 10.1136/gut.2007.135053.CrossRefPubMed

23.

Sarra M, Pallone F, MacDonald TT, Monteleone G: IL-23/IL-17 axis in IBD. Inflamm Bowel Dis. 2010, 16: 1808-1813. 10.1002/ibd.21248.CrossRefPubMed

24.

Wilson MS, Madala SK, Ramalingam TR, Gochuico BR, Rosas IO, Cheever AW, Wynn TA: Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med. 2010, 207: 535-552. 10.1084/jem.20092121.PubMedCentralCrossRefPubMed

25.

Guan Q, Ma Y, Hillman CL, Qing G, Ma AG, Weiss CR, Zhou G, Bai A, Warrington RJ, Bernstein CN, Peng Z: Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis. Mol Med. 2011, 17: 646-656.PubMedCentralCrossRefPubMed

26.

Zorzi F, Monteleone I, Sarra M, Calabrese E, Marafini I, Cretella M, Sedda S, Biancone L, Pallone F, Monteleone G: Distinct profiles of effector cytokines mark the different phases of Crohn’s disease. PLoS One. 2013, 8: e54562-10.1371/journal.pone.0054562.PubMedCentralCrossRefPubMed

27.

Bamba S, Andoh A, Yasui H, Araki Y, Bamba T, Fujiyama Y: Matrix metalloproteinase-3 secretion from human colonic subepithelial myofibroblasts: role of interleukin-17. J Gastroenterol. 2003, 38: 548-554.PubMed

28.

Lawrance IC, Wu F, Leite AZ, Willis J, West GA, Fiocchi C, Chakravarti S: A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology. 2003, 125: 1750-1761. 10.1053/j.gastro.2003.08.027.CrossRefPubMed

29.

Gunther U, Schuppan D, Bauer M, Matthes H, Stallmach A, Schmitt-Gräff A, Riecken EO, Herbst H: Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and −13, and TIMP-1 gene expression. Am J Pathol. 1999, 155: 493-503. 10.1016/S0002-9440(10)65145-0.PubMedCentralCrossRefPubMed

30.

Sharkhuu T, Matthaei KI, Forbes E, Mahalingam S, Hogan SP, Hansbro PM, Foster PS: Mechanism of interleukin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity. Clin Exp Allergy. 2006, 36: 1575-1583. 10.1111/j.1365-2222.2006.02595.x.CrossRefPubMed

31.

Monteleone G, Pallone F, Macdonald TT: Interleukin-25: a two-edged sword in the control of immune-inflammatory responses. Cytokine Growth Factor Rev. 2010, 21: 471-475. 10.1016/j.cytogfr.2010.05.001.CrossRefPubMed

32.

Fichtner-Feigl S, Strober W, Geissler EK, Schlitt HJ: Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis. Mucosal Immunol. 2008, 1 (Suppl.1): S24-S27.PubMedCentralCrossRefPubMed

33.

Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PD, Wehkamp J, Feagan BG, Yao MD, Karczewski M, Karczewski J, Pezous N, Bek S, Bruin G, Mellgard B, Berger C, Londei M, Bertolino AP, Tougas G, Travis SP: Secukinumab in Crohn’s Disease Study Group: Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012, 61: 1693-1700. 10.1136/gutjnl-2011-301668.CrossRefPubMed

34.

Best WR, Becktel JM, Singleton JW, Kern F: Development of a Crohn’s disease activity index: National Cooperative Crohn’s disease study. Gastroenterology. 1976, 70: 439-444.PubMed

35.

Maglinte DD, Kelvin FM, Sandrasegaran K, Nakeeb A, Romano S, Lappas JC, Howard TJ: Radiology of small bowel obstruction: contemporary approach and controversies. Abdom Imaging. 2005, 30: 160-178. 10.1007/s00261-004-0211-6.CrossRefPubMed

36.

Di Sabatino A, Pender SLF, Jackson CL, Prothero JD, Gordon JN, Picariello L, Rovedatti L, Docena G, Monteleone G, Rampton DS, Tonelli F, Corazza GR, MacDonald TT: Functional modulation of Crohn’s disease myofibroblasts by anti-TNF antibodies. Gastroenterology. 2007, 133: 137-149. 10.1053/j.gastro.2007.04.069.CrossRefPubMed

37.

Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT: A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol. 1997, 158: 1582-1590.PubMed

38.

Rodriguez LG, Wu X, Guan JL: Wound-healing assay. Methods Mol Biol. 2005, 294: 23-29.PubMed

Title: The role of interleukin 17 in Crohn’s disease-associated intestinal fibrosis
Authors: Paolo Biancheri
Sylvia LF Pender
Francesca Ammoscato
Paolo Giuffrida
Gianluca Sampietro
Sandro Ardizzone
Amir Ghanbari
Renata Curciarello
Alessandra Pasini
Giovanni Monteleone
Gino R Corazza
Thomas T MacDonald
Antonio Di Sabatino
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Fibrogenesis & Tissue Repair / Issue 1/2013
Electronic ISSN: 1755-1536
DOI: https://doi.org/10.1186/1755-1536-6-13

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The role of interleukin 17 in Crohn’s disease-associated intestinal fibrosis

Abstract

Background

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases

HDAC inhibitors in experimental liver and kidney fibrosis

Function and fate of myofibroblasts after myocardial infarction

The 22nd annual meeting of the European Tissue Repair Society (ETRS) in Athens, Greece

Cyclosporin A reduces matrix metalloproteinases and collagen expression in dermal fibroblasts from regenerative FOXN1 deficient (nude) mice

Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page